Zimmer Biomet Holdings, Inc. (ZBH) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $87.20, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Below 200-MA, MA slope -1.9%/30d (confirmed downtrend).
Zimmer Biomet designs and markets orthopedic reconstructive implants (knees, hips), sports medicine, biologics, extremities, trauma, CMFT, bone cement, and surgical products globally through Americas, EMEA, and Asia Pacific segments. Approximately 85% of net sales are... Read more
Hold if already holding. Not a fresh buy at $87.20, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Below 200-MA, MA slope -1.9%/30d (confirmed downtrend). Chart setup: Death cross but MACD improving, RSI 60. Maintain position. Not compelling to add more. Score 6.0/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 58d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-06-09Recent Developments — Zimmer Biomet Holdings, Inc.
Latest news
- NEWS Zimmer Biomet (ZBH) Plunges to 13-Year Low on Finance Chief Resignation - Insider Monkey — Insider Monkey negative
- NEWS Zimmer Biomet (ZBH) Plunges to 13-Year Low on Finance Chief Resignation - Yahoo Finance — Yahoo Finance negative
- NEWS A Look at Zimmer Biomet Holdings Inc (ZBH) After 10.6% Decline -- GF Value $127.12 vs Price $82.80 - GuruFocus — GuruFocus negative
- NEWS What is dragging Zimmer (ZBH) stock lower | Q4 2025: EPS Beats Forecasts - Global Trading Community - Xã Thanh Hà — Xã Thanh Hà positive
- NEWS ZBH (Zimmer Biomet Holdings Inc.) reports Q4 2025 earnings per share that align perfectly with Wall Street consensus est — Cổng thông tin điện tử tỉnh Tây Ninh positive
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-04-28Item 5.02MEDIUMCFO Suketu Upadhyay resigned effective April 28, 2026 to pursue a new professional opportunity; no disagreement cited. Paul Stellato (VP/Controller/CAO) appointed as interim CFO. Permanent search underway; Stellato remains principal accounting officer.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $87.20, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Below 200-MA, MA slope -1.9%/30d (confirmed downtrend). Chart setup: Death cross but MACD improving, RSI 60. Maintain position. Not compelling to add more. Target $88.83 (+1.9%), stop $82.75 (−5.4%), A.R:R 0.2:1. Score 6.0/10, moderate confidence.
Take-profit target: $88.83 (+1.8% upside). Target $88.83 (+1.9%), stop $82.75 (−5.4%), A.R:R 0.2:1. Stop-loss: $82.75.
Analyst target reached - limited upside remaining; Below 200-MA, MA slope -1.9%/30d (confirmed downtrend).
Zimmer Biomet Holdings, Inc. trades at a P/E of 22.6 (forward 9.7). TrendMatrix value score: 7.5/10. Verdict: Hold.
34 analysts cover ZBH with a consensus score of 3.4/5. Average price target: $99.
What does Zimmer Biomet Holdings, Inc. do?Zimmer Biomet designs and markets orthopedic reconstructive implants (knees, hips), sports medicine, biologics,...
Zimmer Biomet designs and markets orthopedic reconstructive implants (knees, hips), sports medicine, biologics, extremities, trauma, CMFT, bone cement, and surgical products globally through Americas, EMEA, and Asia Pacific segments. Approximately 85% of net sales are consignment-based; no individual customer exceeded 2% of 2025 net sales.